Research output per year
Research output per year
Abstract
Background: Sexual function is an important aspect of human experience, which may significantly contribute to quality of life in patients with schizophrenia (Aizenberg et al., 1995). Antipsychotic drugs can impact upon sexual function.
Methods: A randomised controlled trial compared the impact of atypical versus conventional drugs on sexual function and quality of life in 48 patients with schizophrenia, taking conventional drugs at baseline. The measures used were the self-report Derogatis interview for sexual function (Derogatis, 1997) and Heinrichs QLS (Heinrichs, 1984). Assessments were carried out at baseline and 12 weeks after a switch from conventional antipsychotic treatment to either a conventional or an atypical antipsychotic drug.
Results: A statistically significant increase was found for Derogatis total score at 12-week assessment, compared to baseline, for patients randomised to an atypical antipsychotic drug, compared to patients receiving a conventional agent, using the baseline score as a covariate (F = 6.684, p = 0.014). No statistically significant changes in quality of life scores were seen over the same time period in either group.
Conclusion: These findings suggest that switching from conventional to atypical antipsychotic treatment results in improved sexual function. No change in sexual function was seen in patients who switched from one conventional drug to another. The improvement in sexual function was not linked to an improvement in measured quality of life.
Methods: A randomised controlled trial compared the impact of atypical versus conventional drugs on sexual function and quality of life in 48 patients with schizophrenia, taking conventional drugs at baseline. The measures used were the self-report Derogatis interview for sexual function (Derogatis, 1997) and Heinrichs QLS (Heinrichs, 1984). Assessments were carried out at baseline and 12 weeks after a switch from conventional antipsychotic treatment to either a conventional or an atypical antipsychotic drug.
Results: A statistically significant increase was found for Derogatis total score at 12-week assessment, compared to baseline, for patients randomised to an atypical antipsychotic drug, compared to patients receiving a conventional agent, using the baseline score as a covariate (F = 6.684, p = 0.014). No statistically significant changes in quality of life scores were seen over the same time period in either group.
Conclusion: These findings suggest that switching from conventional to atypical antipsychotic treatment results in improved sexual function. No change in sexual function was seen in patients who switched from one conventional drug to another. The improvement in sexual function was not linked to an improvement in measured quality of life.
| Original language | English |
|---|---|
| Pages (from-to) | 189 |
| Number of pages | 1 |
| Journal | Schizophrenia Research |
| Volume | 67 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2004 |
| Event | 12th Biennial Winter Workshop on Schizophrenia - Davos, Switzerland Duration: 7 Feb 2004 → 13 Feb 2004 |
Fingerprint
Dive into the research topics of 'Antipsychotic drugs and sexual function [Abstract]'. Together they form a unique fingerprint.Research output
- 1 Article
-
Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
Mahmoud, A., Hayhurst, K., Drake, R. & Lewis, S., 16 Jan 2011, In: Schizophrenia Research and Treatment. 2011, p. 1-6 6 p., 596898.Research output: Contribution to journal › Article › peer-review
Open Access
Activities
- 1 Participating in a conference, workshop, exhibition, performance, inquiry, course etc
-
12th Biennial Winter Workshop on Schizophrenia
Karen Hayhurst (Poster presenter)
Feb 2004Activity: Participating in or organising event(s) › Participating in a conference, workshop, exhibition, performance, inquiry, course etc › Research